Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.43 |
| ▸ | ITGAV | P06756 | 3/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27404166 | 0.81 | HTR2C (0.60) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL6320155 | 0.80 | ITGB3 (0.49) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL6327011 | 0.74 | HTR2A (0.45) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL6320693 | 0.71 | POLB (0.45) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL2432912 | 0.70 | FFAR1 (0.53) | HTR2CHTR2BHTR2A | |
| SCHEMBL6251811 | 0.68 | ITGB3 (0.45) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL27270387 | 0.67 | SLC6A12 (0.39) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL6324914 | 0.67 | HTR2A (0.62) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL20595054 | 0.66 | KDM1A (0.45) | ITGB3ITGAVITGB6HTR2CHTR2B | |
| SCHEMBL20595049 | 0.66 | KDM1A (0.45) | ITGB3ITGAVITGB6HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.